Why the study?
Hypertension guidelines usually refer to average patients, but individual characteristics vary substantially, warranting examination of the relationship between comprehensive patient profiles and blood pressure responses.
Does the likelihood of achieving blood pressure control with antihypertensive therapy vary based on composite patient profiles in hypertensive patients?
Does the likelihood of achieving blood pressure control with antihypertensive therapy vary based on composite patient profiles in hypertensive patients?
Answers are grounded in this paper and cite their sources.
Blood pressure control rates in response to antihypertensive therapy vary significantly based on individual patient profiles rather than the specific treatment modality used, highlighting the need for personalized treatment approaches.
Objective: Guidelines on the treatment of hypertensive patients usually refer to ‘average’ patients. However, in clinical practice, individual patient characteristics may differ substantially from the average. Thus, it seems worthwhile to examine the relationship between comprehensive patient profiles and blood pressure responses. Methods: We divided the patient population from the INSIGHT trial into exploration and validation cohorts and constructed composite patient profiles based on predictors of blood pressure control (age, severity of hypertension, comorbidities, and previous treatment status). Next, we tested in the exploration cohort whether blood pressure control rates and adverse effects after 6 months of therapy across these profiles differed from those in the entire patient group. Finally, we explored whether the results from the exploration cohort could be validated using another cohort. Results: Logistic regression analysis showed that the odds of achieving blood pressure control differed substantially between patient profiles but not between treatment modalities. Patients with a less favorable profile (e.g. the combination of age above 60 years, baseline systolic pressure above 160 mmHg, and the presence of diabetes) did less well than patients with a low-risk profile (e.g. absence of organ damage). These results were confirmed in the validation cohort. Conclusion: We conclude that responses to antihypertensive treatment vary in a clinically important manner depending on the composite patient profiles. When found in other trials as well, a priori knowledge about response rates of various patient-profile treatment regimens may help choose the best treatment in individual patients and improve overall blood pressure control rates.
No takes yet. Share an insight, caveat, or question.
Leeuw et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: